Unknown

Dataset Information

0

Risk of methylphenidate-induced prehypertension in normotensive adult smokers with attention deficit hyperactivity disorder.


ABSTRACT: The authors studied predictors of methylphenidate-induced increases in blood pressure (BP). In this secondary analysis of a randomized, double-blind, placebo-controlled smoking cessation trial, nonhypertensive adult smokers with attention deficit hyperactivity disorder randomized to osmotic-release oral system methylphenidate (OROS-MPH) (n=115) were matched one-to-one on baseline systolic BP (SBP) (±5 mm Hg) with participants randomized to placebo (n=115) and followed for 10 weeks. In adjusted mixed linear models of SBP and diastolic BP (DBP), baseline normal SBP (P<.0001) and DBP (P<.0001) were associated with significant OROS-MPH-induced increases compared with placebo, whereas significant increases were not observed in participants with baseline prehypertensive SBP (P=.27) and DBP (P=.79). Participants randomized to OROS-MPH with baseline normal BP had increased odds of developing either systolic (odds ratio [OR], 3.32; 95% confidence interval [CI], 1.41-8.37; P=.006) or diastolic prehypertension (OR, 4.32; 95% CI, 1.56-14.0; P=.004) compared with placebo using simple logistic regression. The authors demonstrated an augmented OROS-MPH-induced BP elevation and risk of prehypertension in adults with baseline normal BP. Significantly increased BP was not observed in adults with baseline prehypertension.

SUBMITTER: Westover AN 

PROVIDER: S-EPMC3556994 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC2913299 | biostudies-literature
2014-09-05 | E-GEOD-52889 | biostudies-arrayexpress
2014-09-05 | GSE52889 | GEO
| S-EPMC5789875 | biostudies-literature
| S-EPMC8092481 | biostudies-literature
| S-EPMC8763351 | biostudies-literature
| S-EPMC8869321 | biostudies-literature
| S-EPMC10042435 | biostudies-literature
| S-EPMC3139835 | biostudies-literature
| S-EPMC5583388 | biostudies-literature